Inovio Received FDA Feedback Saying That The Data From Its Completed Phase 1/2 Trial Of INO-3107 For Recurrent Respiratory Papillomatosis Could Support Marketing Application Submission Under The Accelerated Approval Program
Portfolio Pulse from Benzinga Newsdesk
Inovio Pharmaceuticals has received feedback from the FDA indicating that data from its completed Phase 1/2 trial of INO-3107 for Recurrent Respiratory Papillomatosis could support a marketing application submission under the Accelerated Approval Program.
October 10, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's positive feedback on Inovio's INO-3107 could potentially expedite the drug's approval process, which may positively impact the company's stock in the short term.
The FDA's positive feedback is a significant step towards the approval of INO-3107. If the drug is approved under the Accelerated Approval Program, it could lead to increased revenues for Inovio, which would likely be reflected in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100